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s Our Understanding of Restenosis Changing?*
loke V. Finn, MD,‡ Gaku Nakazawa, MD,†
rank D. Kolodgie, PHD,† Renu Virmani, MD†
aithersburg, Maryland; and Atlanta, Georgia
rug eluting stents (DES) were designed with the primary
urpose of inhibiting neointimal formation after percutane-
us coronary intervention. Early data from randomized
linical studies confirmed the efficacy of these devices in
reventing restenosis when compared with bare-metal
tents (BMS) 6 to 8 months after implantation (1,2).
owever, given that the period of drug release is relatively
hort (i.e., 90 days) after DES implantation in animal
odels and that preclinical studies done by us and others
emonstrate a late “catch-up phenomenon” in terms of an
ncrease in neointimal thickness from 1 to 3 months, an
mportant unanswered question remains: ”Do DES halt the
estenotic process or merely delay it?” (3–5). Our data from
uman pathology from patients dying after DES placement
ndicate incomplete healing as long as 50 months after
evice placement (6).
See page 291
In this issue of JACC: Cardiovascular Interventions, Byrne
t al. (7) present data from an observational study of patients
eceiving permanent polymer rapamycin-eluting stents
RES), permanent polymer paclitaxel-eluting stents (PES),
r polymer-free rapamycin-eluting stents (pf-RES) who
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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orporation.nderwent serial angiographic follow-up at 6 to 8 months
i.e., early) and 2 years (i.e., late) after stent placement. The
ES and PES demonstrated significant increases in late
umen loss from early to late follow-up, whereas pf-RES
howed essentially no change. These data demonstrate that
he arterial response to these devices is a dynamic process
asting well beyond the 6-month time point chosen for
ngiographic follow-up in clinical trials and highly depen-
ent on the type of DES (i.e., polymeric vs. nonpolymeric)
s well as the duration of drug release. These factors might
eavily influence the temporal course of intimal formation
nd healing after DES placement. This study also puts in
oubt the belief that polymeric slow release of the drug is
ssential for long-term efficacy of DES.
Much of our current understanding of the vascular
esponses to DES has been generated from animal data.
iven the limited resolution of conventional angiography,
ntravascular ultrasound, or other modalities, preclinical
istological studies remain the most effective means of
valuating arterial responses to vascular stent implants and
ave helped lend insights into human responses (8). Al-
hough arterial repair after stent placement in normal
nimal arteries occurs more rapidly than in humans, the
equence of biological responses are remarkably similar (9).
oth RES and PES differ from pf-RES in that they contain
urable polymers, which serve to extend the duration of
rug release but remain as permanent implants capable of
rovoking their own inflammatory responses in the arterial
all. In contrast, pf-RES contains no polymer but instead
onsists of 316L stainless steel microporous surface onto
hich rapamycin is directly sprayed (10).
In animal models, the duration of drug release of the 3
ystems is very different. Wessely et al. (10) demonstrated in
he porcine model that pf-RES elute two-thirds of their
rug in the first week and nearly all of the loaded dose by 21
ays, whereas RES stents elute only 68.4% at 28 days (3,10).
oreover, tissue levels peak at 3 days with pf-RES as
ompared with 14 days with the RES. The temporal release
f PES is quite different with a slow release occurring over
t least 28 days with the rest “sequestered within the
olymer.”
These release kinetics translate into very different
rterial histologic responses. Although the initial re-
ponse to polymeric RES and PES is a significant
ecrease in neointimal growth at 28 days compared with
MS, both stents demonstrate increases in intimal for-
ation beyond this time point such that the initial
ntirestenotic benefit is lost, which was also reinforced by
linical studies (11,12) (Fig. 1). Although no long-term
ata exist in animal models for pf-RES, responses resem-
le that of the BMS with similar amounts of fibrin
eposition, inflammation, and endothelialization at 28
ays in the porcine and rabbit models (10). These data
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301f-RES exists or not. In general, both in humans and in
nimals, BMS results in an early peak in intimal forma-
ion with regression of neointima thereafter (13,14).
here is no reason to suspect that the response to pf-RES
ould be any different than BMS, as was seen histolog-
cally in our laboratory.
Two factors are likely responsible for the differing pattern
f neointimal growth seen in polymeric DES versus pf-
ES. These are differences in duration of drug release and
nflammatory responses to polymer. The short duration of
rug release in pf-RES essentially translates into BMS-like
esponses with complete healing at 28 days in animal
odels. In the rabbit model polymeric RES demonstrate
ignificantly increased fibrin and decreased endothelialization
hen compared with BMS. These data indicate that, for
olymeric DES, arterial healing is incomplete at 28 days and
hat unlike BMS arterial repair continues beyond this time
oint. Therefore it is not surprising that, in humans, changes in
eointimal growth occur far beyond the normal time point at
hich healing is complete in BMS (i.e., 6 months).
In addition, the durable polymers on RES (polyethylene-
o-vinyl acetate [PEVA] and poly n-butyl methacrylate
Figure 1. Long-Term Outcomes in Porcine Coronary Artery Model and Huma
(A) The bar chart shows neointimal thickness in porcine coronary artery after C
days in drug-eluting stent, whereas in bare metal stent (BMS) no such increase
with Cypher and Taxus stent from 1 to 5 years in the SIRIUS and TAXUS IV tria
progressively with each year.PBMA]) and PES (poly[styrene-b-isobutylene-b-styrene]) rrovide an additional factor that influences local responses and
ight alter processes involved in neointimal formation. Each
olymer provokes a distinctive inflammatory response in ani-
als. In an overlapping rabbit model of stent deployment, we
reviously reported that RES implants were characterized by
iant cell infiltration around stent struts, whereas PES pro-
oked a heterophil/eosinophilic reaction (15). The porcine
odel demonstrates a progressive granulomatous and eosino-
hilic reaction to Cypher stent starting at 28 days and increas-
ng out to 1 year (14). The likely explanation for these findings
s a local hypersensitivity reaction to the nonerodable polymers
sed on the Cypher stents (PEVA and PBMA), because it
eaks only after the complete release of drug (i.e., 60 days).
arter et al. (4) have also reported similar findings in the
orcine model, with western blot of stented porcine coronary
rteries at 90 days demonstrating ongoing cellular proliferation
espite elevation of p27kip1, a mediator of the antiproliferative
ffects of rapamycin. These data support the notion that
olymers in DES might provoke chronic inflammation, which
ight be a potential driver of intimal formation, diminishing
ver a long term with decreased efficacy of these systems.
In contrast, pf-RES provoke little if any inflammatory
ical Trials
r and Taxus (overlapping) implantation. Note “late catch-up“ from 28 to 90
served (14). (B) Bar graph showing clinical follow-up of patients implanted
pectively (11,12). Similarly, target lesion revascularization (TLR) is increasingn Clin
yphe
is ob
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302ompared with BMS in the rabbit model. Although sup-
orting the biocompatibility of this system, these data call
nto question the clinical antirestenotic efficacy reported by
yrne et al. (7). Previous nonpolymeric delivery of paclitaxel
ith a different system as reported by Park et al. (16)
ssociated with less neointimal formation at 6 months, but
his benefit was lost at 2 years especially in the high-dose
aclitaxel arm. Heterogeneity of patient characteristics and
esions in the study by Bryne et al. complicates its interpre-
ation, especially given that there were 2 follow-up time
oints. It is entirely possible that the characteristics of each
roup at early and late follow-up were different between
tent arms, especially because patients who underwent
evascularization were excluded for late follow-up analysis.
n addition, the late restenosis rate is higher than has been
eported by others, with composite in-segment binary re-
tenosis being 17.3% for RES, 16.6% for pf-RES, and
1.8% for PES.
In summary, we believe these data support the notion that
he vascular responses to pf-RES result in less delay in
ealing and diminished inflammatory responses compared
ith RES or PES but might be burdened with fewer
fficacies. We can surmise that the data of Byrne et al.
upport the concept that, although DES delay intimal
ormation and healing, they do not halt it. As seen in
nimals, the 2 primary mechanisms responsible for driving
he increase in intimal formation between 6 to 8 months and
years in humans is likely: 1) ongoing arterial repair that is
ccelerated in the face of decreasing drug levels; and 2)
hronic inflammatory responses to polymer or excessive
brin deposition, with both processes provoking cellular
roliferation.
Practically speaking, these data also inform the way we
hould care for patients after DES placement. Whereas the
urveillance period for symptoms of restenosis in patients
eceiving BMS is usually 6 months, clinicians need to be
ware that polymeric DES have altered the temporal course
f restenosis. In the study of Byrne et al. (7), of the 1,471
on-restenotic lesions at 6 to 8 months, 12% met the criteria
or binary angiographic restenosis at 2 years, which is higher
han that reported at 6 to 8 months, whereas pf-RES had
igher restenosis at 6 to 8 months, but the restenosis did not
ncrease at 2 years. These data highlight the need for
ontinued surveillance in these patients well beyond that
eeded for patients receiving BMS and reminds us that, as
e enlarge our understanding of DES technology, contin-
ed refinements in the care of these patients are needed. seprint requests and correspondence: Dr. Renu Virmani, CV-
ath, Institute, Inc., 19 Firstfield Road, Gaithersburg, Maryland
0878. E-mail: rvirmani@cvpath.org.
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